Back to Search
Start Over
Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia withNPM1andFLT3‐internal tandem duplication genotypes
- Source :
- Cancer. 125:1091-1100
- Publication Year :
- 2018
- Publisher :
- Wiley, 2018.
-
Abstract
- BACKGROUND The revised 2017 European LeukemiaNet (ELN) classification (ELN-2017) of acute myeloid leukemia (AML) divides patients into 3 prognostic risk categories, with additional factors such as the fms-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) allele ratio (AR) considered for risk stratification. To the best of the authors' knowledge, the prognostic usefulness of ELN-2017 in comparison with ELN-2010 in younger patients with AML has not been validated to date. METHODS The authors performed a retrospective study on patients aged
- Subjects :
- Male
Oncology
Cancer Research
Leukocyte Count
European LeukemiaNet
0302 clinical medicine
hemic and lymphatic diseases
Antineoplastic Combined Chemotherapy Protocols
030212 general & internal medicine
Cytarabine
Hematopoietic Stem Cell Transplantation
Nuclear Proteins
Myeloid leukemia
Induction Chemotherapy
Middle Aged
Prognosis
Europe
Survival Rate
Leukemia, Myeloid, Acute
030220 oncology & carcinogenesis
Cohort
Female
Nucleophosmin
medicine.drug
Adult
medicine.medical_specialty
NPM1
Adolescent
Risk Assessment
Article
Young Adult
03 medical and health sciences
Internal medicine
medicine
Humans
Idarubicin
Retrospective Studies
L-Lactate Dehydrogenase
Platelet Count
business.industry
Reproducibility of Results
Induction chemotherapy
Retrospective cohort study
Consolidation Chemotherapy
fms-Like Tyrosine Kinase 3
Mutation
business
Subjects
Details
- ISSN :
- 10970142 and 0008543X
- Volume :
- 125
- Database :
- OpenAIRE
- Journal :
- Cancer
- Accession number :
- edsair.doi.dedup.....f3c81d7d640b9629ed1dd4bff03dedba
- Full Text :
- https://doi.org/10.1002/cncr.31885